Amgen is expanding its cancer and inflammation biosimilar presence in China with a new deal with Simcere.
In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Allergan says CFO Tessa Hilado, which came to Allergan three years ago, is retiring but agreed to stay on until her replacement is named.
Despite lots of value-based talk, a new PwC survey finds the new payer contracting approach has yet to take off in a major way.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Big Pharma expanded in emerging markets by 6.1% last quarter, but GSK and Eli Lilly didn't reap as much growth as their peers
In a biosimilars case with blockbuster implications, Pfizer sued J&J, calling its strategy for fighting off Remicade biosimilars "anticompetitive.…
Kåre Schultz has yet to take over at beleaguered Teva, but he is already getting advice on what to do from some of this investors.
AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.
Teva unveiled terms to sell its remaining women's health products, gaining $1.38 billion that'll go toward paying down debt.
After Johnson & Johnson's Zytiga put up notable prostate cancer data, Astellas and Pfizer needed a win for their medicine Xtandi. Now they have one.